<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868916</url>
  </required_header>
  <id_info>
    <org_study_id>CR108926</org_study_id>
    <secondary_id>74765340RPG0001</secondary_id>
    <nct_id>NCT04868916</nct_id>
  </id_info>
  <brief_title>An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa</brief_title>
  <official_title>Prospective Observational Study to Estimate the Genotype and Phenotype of Japanese Patients With X-linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify a cohort of Japanese participants with X-linked&#xD;
      retinitis pigmentosa (XLRP) associated with pathogenic variants in the retinitis pigmentosa&#xD;
      GTPase regulator (RPGR) gene and to investigate their associated phenotype.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2021</start_date>
  <completion_date type="Anticipated">August 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 3, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Function</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>Visual function will be assessed using visual acuity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Structure</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>Retinal structure will be assessed using spectral domain optical coherence tomography (SDOCT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Function</measure>
    <time_frame>Up to Day 30</time_frame>
    <description>Retinal function will be assessed using static visual field testing.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>X-Linked Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Participants with X-Linked Retinitis Pigmentosa (XLRP)</arm_group_label>
    <description>Participants with confirmed diagnosis of XLRP associated with pathogenic variants in retinitis pigmentosa GTPase regulator (RPGR) in the Japanese population will be enrolled in the study and the data will be collected and observed. The primary data source for this study will be the medical records of each participant.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consists of Japanese participants with X-linked retinitis pigmentosa&#xD;
        (XLRP) associated with pathogenic variants in retinitis pigmentosa GTPase regulator (RPGR).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have RPGR-associated retinal dystrophy&#xD;
&#xD;
          -  Are able to give informed consent or assent, with the guidance of their&#xD;
             parent/guardian where appropriate&#xD;
&#xD;
          -  Are able to undertake age-appropriate clinical assessments as specified in the&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are unable or unwilling to undertake consent or clinical testing&#xD;
&#xD;
          -  Participated in another research study and had intraocular surgery within 3 months of&#xD;
             screening&#xD;
&#xD;
          -  Significant ophthalmologic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center</name>
      <address>
        <city>Tokyo</city>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108926</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

